Creating value through responsible business

ESG Investor Call
September 18, 2017

Jürgen Brokatzy-Geiger, Global Head Corporate Responsibility
Vas Narasimhan, Global Head Drug Development & Chief Medical Officer
Shannon Klinger, Chief Ethics & Compliance Officer and Head Litigation
Disclaimer

This presentation contains expressed or implied forward-looking statements, including discussions of our strategy, research and development activities and pipeline. Such forward-looking statements reflect the current views of the Group regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results expressed or implied by such statements. These expectations could be affected by, among other things, risks and factors referred to in the Risk Factors section of Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this presentation as of this date and does not undertake any obligation to update it in the future.
Welcome

Vas Narasimhan
Global Head of Drug Development and
Chief Medical Officer for Novartis

Jürgen Brokatzky-Geiger
Global Head Corporate Responsibility

Shannon Klinger
Chief Ethics & Compliance Officer and
Head Litigation
Agenda

1. Novartis corporate responsibility focus
2. Research & Development
3. Ethics & Compliance
4. Corporate Responsibility
5. Questions
Our CR strategy is rooted in our mission and vision

Expanding access to healthcare

- Control and eliminate diseases
- Pioneer new business approaches and healthcare delivery models
- Find new treatments

Doing business responsibly

- Striving for ethical and sustainable business practices
  - Care for our associates
  - Promote ethics and strengthen governance
  - Strive for environmental sustainability
Agenda

1. Novartis corporate responsibility focus
2. Research & Development
3. Ethics & Compliance
4. Corporate Responsibility
5. Questions
Novartis R&D reimagining medicine and addressing areas of high unmet medical need

1. Focus on operational agility and productivity with goal to invest ~20% of Innovative Medicines sales in R&D to continue to advance science

2. Broad early and late stage pipeline with depth and quality assets in each therapeutic area
   Focus on medicines that matter

3. Comprehensive R&D pipeline for tropical medicines to target conditions with high unmet medical need
**Continued strong track record of R&D excellence at Novartis**

<table>
<thead>
<tr>
<th>Metric</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Projects in the clinic</td>
<td>175+</td>
</tr>
<tr>
<td>New molecular entities in the clinic</td>
<td>90+</td>
</tr>
<tr>
<td>Development units with therapeutic area focus</td>
<td>8</td>
</tr>
<tr>
<td>Breakthrough Therapy designations&lt;sup&gt;1&lt;/sup&gt;</td>
<td>16</td>
</tr>
<tr>
<td>Active clinical trials</td>
<td>500+</td>
</tr>
</tbody>
</table>

---

1. Since the introduction of Breakthrough Designation pathway by the FDA, Novartis pipeline included a total of 16 breakthrough designations cumulatively of which 13 are currently actively under development or in approved indications. Includes products in-licensed (with BTD granted prior to the acquisition of the asset) or out-licensed (with BTD granted to Novartis prior to divestment).
R&D priorities to lead the industry in innovation into the future

Continuously strengthening the portfolio of therapies

Building an industry-leading “intelligent, agile” organization

Addressing the major unmet needs of today

Digitally enabled productivity

Focusing on medicines that matter

Next-gen platform for data science
Broad early and late stage pipeline in several therapeutic areas

Selected key assets

**Oncology**
- BYL719+fulv. Breast cancer
- Kymriah® (CT019) Ped. ALL+ DLBCL
- INC280® NSCLC
- Jakavi®2 Multiple
- Kisqali®3 Multiple
- Rydapt® AML and adv. SM
- SEG101 Sickle cell disease
- Signifor® LAR Cushing’s disease
- Tafinlar® + Mekinist® BRAF V600+ NSCLC
- Tafinlar® + Mekinist® BRAF V600+ melanoma (adjuvant)
- Tasigna® CML treatment free remission
- Zykdia® ALK+ NSCLC (brain metastases)
- 18 IO assets incl. combos (Multiple)
- ABL001 CML

**Cardio-Metabolic**
- ACZ885 CV risk reduction
- Entresto® (Multiple)
- APO(a)-LRx High risk CVRR
- APOCIII-LRx High risk CVRR
- LIK066 Weight loss
- LHW090 Resistant hypertension
- MAAS68 Stroke prevention
- MAA868 Stroke prevention

**Ophthalmology**
- RTH258 (Multiple)
- Lucentis® ROP
- UNR844 (Presbyopia)
- ECF843 Dry eye

**Respiratory**
- QAW039 Asthma
- QMF149 Asthma
- QVM149 Asthma
- QBW251 Cystic fibrosis/COPD

**Immunology & Dermatology**
- AMG 334 Migraine
- BAF312 Relapsing MS
- EMA401 Neuropathic Pain
- Gilenya® Pediatric MS
- OMB157 Relapsing MS
- CNP520 Alzheimer’s disease
- BYM338 Multiple
- LMI070 Spinal muscular atrophy
- QGE031 Chronic spontaneous urticaria
- CJM112 Multiple immune disorders
- VAY736 Prim. Sjögren’s syndr.
- VAY7851 NASH
- LJNI452 NASH
- ZPL389 Atopic dermatitis

**Established medicines & Anti-infectives**
- Lamprene® MDR-TB
- Egaten® Faszioliasis
- KAF156 Malaria
- KAE609 Malaria
- Lumeferantrine SDF® Malaria

**Biosimilars**
- Adalimumab
- Rituximab
- Infliximab
- Etanercept
- Pegfilgrastim

1. Emricasan 2. licensed in from Incyte 3. LEE011 was developed by the Novartis Institutes for BioMedical Research (NIBR) under a research collaboration with Astex Pharmaceuticals
4. Solid dispersible formulation
Decades of commitment to address tropical diseases like Malaria

1942
The J.R. Geigy AG launches insecticide Gesarol® (DDT)

1943
The Swiss Tropical and Public Health Institute is founded by Rudolf Geigy the son of Johann Rudolf Geigy

1997
Novartis commits to make the fight against malaria key aspect of the company's access-to-medicine programs

1999
Novartis launches Coartem® the first fixed-dose artemisinin based combination therapy (ACT)

2009
Novartis launches Coartem® Dispersible, the first dispersible ACT specifically developed for infants and children with malaria

2016
Launch of SMS for Life 2.0 in Nigeria

2017
Novartis advancing 2 drug candidates with new mechanisms of action in phase II trials
R&D programs for Tropical Medicines
Collaboratively targeting conditions with high unmet medical need

**Drug Discovery**
Novartis Institute for Tropical Diseases, Emeryville, CA

- Malaria
- Dengue Fever
- Human African Trypanosomiasis
- Chagas Diseases
- Leishmaniasis
- Cryptosporidiosis

**Drug Development**
Anti-Infectives Development Unit, Basel and East Hanover

- Lamprene® (MDR-TB)
- Egaten® (Fascioliasis)
- KAF156 (Malaria)
- KAE609 (Malaria)
- Lumefantrine SDF¹ (Malaria)

All trademarks and logos are property of the respective owners. 1. solid dispersible formulation
Ongoing Drug Discovery Efforts in Malaria
Applying what we have learnt from nine years of anti-malarial drug discovery

Research priorities
• Identify clinical candidates to support new combination therapies with Single Encounter Radical Cure and Prophylaxis (SERCaP) potential
• Enable *P. vivax* radical cure drug discovery

- Novel targets (e.g. PfATP4, PI4K)
- Novel High Throughput Screen assays
- Robust and predictive animal models
- Challenge models & preclinical PK/PD data

HTS to clinical Proof-of-Concept in less than six years for two novel compounds (KAE609 & KAF156)
Current Development Programs in Malaria
Targeting various stages of the parasite life cycle

Two drug candidates (KAE609 and KAF156) in phase II development

KAE609
(spiroindolone)

KAF156
(imidazolopiperazine)

Source: Diagana, Drug Discovery Today (2015)
Recent field visit to our partners in Africa to show our ongoing commitment
Agenda

1. Novartis corporate responsibility focus
2. Research & Development
3. Ethics & Compliance
4. Corporate Responsibility
5. Questions
Meeting society’s changing expectations

• We must deliver good results for our shareholders in the right way to be a trusted leader in changing the practice of medicine

• We are committed to meet society’s changing expectations in a way that we can be proud of

• We are building on a robust foundation with our revised Values & Behaviours, a clear Code of Conduct and a strong tone from the top

• We continue our journey of driving high performance with integrity in close collaboration with our business, Legal, Finance, Internal Audit and Business Practice Office teams

• Key progress 2016 to 2017:
  1. Further strengthened our Integrity & Compliance (I&C) Function
  2. Enhanced compliance policies and processes to drive proactive risk management
  3. Further strengthened our culture of integrity
  4. Aligned on clear focus areas
Further strengthened our I&C function

Developing I&C Talent to have the right people with the right capabilities

- Built a stronger and more diverse Compliance Leadership Team
- Improved cross-divisional talent exchanges and increased ownership of the functional reporting line through new cross-divisional talking talent process
- Continue to develop leadership and technical skills of our I&C professionals

Further strengthened monitoring and reporting

- Strengthened the ability to proactively and strategically mitigate risks and enhanced our monitoring capabilities
- Shared lessons learned from our country & monitoring visits across the organization
- Completed external review of Innovative Medicine’s Compliance Program
- Launched a new Compliance Operations Dashboard that provides centralized data, aggregation, trends identification / analyses and automated reporting of risks
- We are evolving our management reporting to focus even more on trend-identification and compliance effectiveness metrics
Measuring progress

Strengthening the I&C Function

I&C resources

<table>
<thead>
<tr>
<th>Year</th>
<th>I&amp;C Resources</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016</td>
<td>375 FTEs</td>
</tr>
<tr>
<td>2017</td>
<td>475 FTEs</td>
</tr>
</tbody>
</table>

+100 FTEs +27%

I&C Client Satisfaction Survey in 2016

- 66% of respondents said that they were likely to recommend our services
- 3.5/5 satisfaction with I&C services
- 145 participants recognized individuals for excellent services

Continuous training

Code of Conduct e-training 2016

- 98%[^1]

Anti-Bribery e-training 2016[^2]

- 97%[^1]

Enhancing monitoring efforts

Country & monitoring visits

<table>
<thead>
<tr>
<th>Year</th>
<th>Visits</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016</td>
<td>&gt;150</td>
</tr>
<tr>
<td>2017</td>
<td>&gt;250</td>
</tr>
<tr>
<td>2018</td>
<td>300</td>
</tr>
</tbody>
</table>

+100 visits +60%

Driving speak-up

As per 29 August 2017

- Allegations substantiated
- Misconduct cases reported

<table>
<thead>
<tr>
<th>Year</th>
<th>Allegations</th>
<th>Misconduct cases reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>1012[^3]</td>
<td>300</td>
</tr>
</tbody>
</table>

[^1]: 1. of invited population
[^2]: 2. as of 31 March 2017
[^3]: The number of substantiated allegations may change due to the fact that investigation reports with assessments are received on an ongoing basis which potentially leads to a difference of numbers at a later stage.
[^4]: 4. The number of misconduct cases reported may change as matters may be reassessed in the course of the case lifecycle.
We continue to focus on third parties given the potential risk

Highlights of updated Anti-Bribery Third Party Guideline

- We introduced a risk based approach to prioritize efforts and increase effectiveness
- We use a third party firm (Ethixbase) specialized in anti-bribery to support due diligences resulting in greater consistency and higher professionalism
- Better decision-making by involving appropriate stakeholders
- Roll-out supported with a variety of materials and activities to raise awareness and in-depth understanding

Strengthening Third Party Risk Management beyond Anti-Bribery

- Project launched to strengthen Third Party Risk Management holistically across various risk areas by bringing greater consistency to the end-to-end management of third parties
One harmonized principle-based Professional Practices Policy (P3)

- The harmonized P3 Policy provides one standard for Novartis
- The 5 Principles are aligned to our values and easy to remember
- The Novartis reputation is at the center of everything we do
- Embedding these 5 Principles into how we operate will help address new and emerging risks
Global Employee Survey 2017
Integrity included in our areas of strengths

The Code of Conduct has been communicated to me so that I understand it

I feel confident that products and services introduced by my company help improve patient health

In my team, people feel comfortable asking for advice when faced with an ethical decision related to the Code of Conduct

In my team, we have a clear understanding of our patients’ / customers’ needs

Speaking up is valued in my team

<table>
<thead>
<tr>
<th>Statement</th>
<th>% Fav</th>
<th>% Neutral</th>
<th>% Unfav</th>
<th>Significantly Above Comparison</th>
<th>Significantly Below Comparison</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Code of Conduct has been communicated to me so that I understand it</td>
<td>92</td>
<td>6</td>
<td>2</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>I feel confident that products and services introduced by my company help improve patient health</td>
<td>92</td>
<td>7</td>
<td>1</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>In my team, people feel comfortable asking for advice when faced with an ethical decision related to the Code of Conduct</td>
<td>82</td>
<td>14</td>
<td>4</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td>In my team, we have a clear understanding of our patients’ / customers’ needs</td>
<td>85</td>
<td>11</td>
<td>4</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>Speaking up is valued in my team</td>
<td>77</td>
<td>14</td>
<td>10</td>
<td>11</td>
<td></td>
</tr>
</tbody>
</table>

1. Global Top Norm: contains responses from employees across the globe and different industries. Norm group contains responses from companies with 90th percentile favorable score for each survey item.
Continuous learning from the outside world and own mistakes

Immediate action and transparent communication

- Occasionally we do discover compliance lapses, which are most often related to legacy practices
- In case of issues, we take immediate action and ensure that those same activities are not taking place in other parts of our organization
- We enhance transparency in internal and external communication

Continuous learning

- Launched series “insights from the outside” to increase external focus and to learn from other industries and the outside world
- Developed integrity case studies for managers to use in discussion with their team, inspired by real-life scenarios
- Business Practices Office case studies to learn from past misconduct
- Guides to help markets learning from relevant audits
Culture change accelerates when compliance is embedded in key processes / initiatives

1. Risk discussions systematically included in business reviews with management
2. All employees need to identify 2-3 things which they have done to drive a culture of integrity (performance appraisal)
3. Compliance / reputation risks considered as part of target discussions with management
4. Compliance results factored into performance ratings of region and country heads
5. Integrity story-telling campaign to all employees launched
Clearly defined focus areas

Leaders
- Functional accountability
  - Leaders’ accountability
- Tone at the top
  - Plus tone at the middle

Employees
- Following rules
  - Making judgement calls

Integrity & Compliance
- Siloed mentality
  - Enterprise connectors
- Enforcer
  - Problem solver
Agenda

1. Novartis corporate responsibility focus
2. Research & Development
3. Ethics & Compliance
4. Corporate Responsibility
5. Questions
Corporate Responsibility:
Key progress 2016 to 2017

1. Expanded **Stakeholder Engagement Activities**

2. Expanded **Novartis Access** focused on 15 on- and off-patent medicines addressing non-communicable diseases

3. Moved from #4 to **#3 in the Access to Medicine Index** and are recognized as the leader in access to medicine management

4. Improved our rank to #4 in the **Dow Jones Sustainability Index (DJSI) World Index** and also re-entered the **DJSI Europe Index**

5. Listed **#4 on FORTUNE’s Change the World** list

6. Published **2016 US Transparency and Patient Access Report**

7. The **Access to Medicine Committee** reviewed Division/Business Unit implementation the Novartis Access Strategy Framework

8. Mapped Novartis corporate **human rights** risks and opportunities

9. Conducted **impact valuation** pilots in Kenya and China

10. Expanded **corporate volunteering** activities

---

1. Next Stakeholder Event November 21, 2017 - Exploring the future of access to healthcare in lower-income countries: what will drive success? [registration](#)
Our access strategy: tailoring our approach to income segments

<table>
<thead>
<tr>
<th>Income segments¹</th>
<th>% of population size</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIGH INCOME</td>
<td>7 %</td>
</tr>
<tr>
<td>UPPER-MIDDLE INCOME</td>
<td>9 %</td>
</tr>
<tr>
<td>MIDDLE INCOME</td>
<td>13 %</td>
</tr>
<tr>
<td>LOW INCOME</td>
<td>55 %</td>
</tr>
<tr>
<td>POOR</td>
<td>16%</td>
</tr>
</tbody>
</table>

Access approaches

- Traditional for-profit business-led approach (original brands & generics)
- Patient assistance programs
- Generics
- Differential pricing

Novartis Social Business

- Patient assistance programs
- Philanthropy

¹. PEW Research Center with data from World Bank PovcalNet (data 2011)
Novartis Social Business: Capitalizing on proven industry-leading programs

- We offer **commercial solutions** to support public health needs and increase patient reach

- We devise novel approaches to **tackle infectious and chronic disease** and partner with public and private actors to **build capacity**

- We aim to become a partner of choice in improving access to healthcare for patients in lower income countries
Novartis Access 20 months update

- **180,000+ monthly treatments** delivered to Kenya, Ethiopia and Lebanon (through ICRC)
- **Uganda** fifth country to sign MoU after Kenya, Ethiopia, Rwanda and Pakistan
- **7 partnerships** with faith-based organizations, NGOs, academia and research organizations
- **Capacity-building** activities started in Kenya to screen and diagnose people for diabetes and hypertension
- Discussions ongoing in **10+ countries** across 3 continents to introduce the program
- **437 products submitted** to health authorities for regulatory approval in **23 countries** (161 approvals to date)
Materiality Assessment 2017 - full exercise started in Q4 2016

Approach

- Builds on 2013 methodology (recognized as best practice by CR standard setters)
- Combination of quantitative (survey) and qualitative input (interviews)
- Inclusive list of internal and external stakeholders (among others, representatives from the investor community)
- New elements to gain deeper insights:
  - Factor analysis
  - Risk & opportunity evaluation Scenario analysis
  - Strategy workshops

<table>
<thead>
<tr>
<th>Q4 2016</th>
<th>Q1 2017</th>
<th>Q2 2017</th>
<th>Q3 2017</th>
<th>Q4 2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Business Buy-In</td>
<td>Internal Assessment</td>
<td>External Assessment</td>
<td>Data Analysis / Evaluation &amp; Validation</td>
<td>Strategic Integration</td>
<td></td>
</tr>
<tr>
<td>Survey: ca. 1400 participants Interviews: ca. 30</td>
<td>Survey: ca. 200 participants Interviews: ca. 30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Introduction: Patrice Matchaba, Novartis Global Head Corporate Responsibility
Questions
Back-up
## Access initiatives KPIs

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Novartis Access</td>
<td>8</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Healthy Family (in India, Kenya, Vietnam and Indonesia)</td>
<td>610</td>
<td>981</td>
<td>788</td>
<td>7,756</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>618</strong></td>
<td><strong>984</strong></td>
<td><strong>788</strong></td>
<td><strong>7,756</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patient assistance programs</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Novartis Patient Assistance Foundation Inc. (US)</td>
<td>45</td>
<td>42</td>
<td>61</td>
<td></td>
</tr>
<tr>
<td>Oncology/Hematology LMIC patient assistance</td>
<td>83</td>
<td>81</td>
<td>75</td>
<td></td>
</tr>
<tr>
<td>Alcon US patient assistance</td>
<td>6</td>
<td>8</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>134</strong></td>
<td><strong>131</strong></td>
<td><strong>146</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Zero-profit model</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Malaria/Coartem®</td>
<td>49,758</td>
<td>64,098</td>
<td>70,028</td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>49,758</strong></td>
<td><strong>64,098</strong></td>
<td><strong>70,028</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Donations</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcon medical missions</td>
<td>484</td>
<td>394</td>
<td>439</td>
<td></td>
</tr>
<tr>
<td>Leprosy (World Health Organization)</td>
<td>290</td>
<td>305</td>
<td>308</td>
<td></td>
</tr>
<tr>
<td>Fascioliasis/Egaten®</td>
<td>276</td>
<td>14</td>
<td>233</td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>1,050</strong></td>
<td><strong>712</strong></td>
<td><strong>980</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Health systems strengthening</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Novartis Foundation</td>
<td>8,909</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Novartis research capacity-building programs</td>
<td>1.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>8,910</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| **Grand Total**                                             | **51,561**| **65,925**| **71,942**| **16,666**|

---

**Note:**

- **Patients reached (`000s`)** refer to the number of patients who have benefited from the initiatives.
- **People reached (`000s`)** include both patients and other beneficiaries such as healthcare providers and caregivers.
- **Zero-profit model** initiatives focus on specific diseases like Malaria and Leprosy.
- **Health systems strengthening** includes programs aimed at enhancing healthcare infrastructure and capacity.
Pioneering sustainable and scalable business models...

<table>
<thead>
<tr>
<th>Novartis Access</th>
<th>NGO supply</th>
</tr>
</thead>
<tbody>
<tr>
<td>180,000 treatments for chronic conditions delivered at USD 1 per treatment per month to date</td>
<td>500,000 treatments pediatric amoxicillin treatment courses delivered to UNICEF to date</td>
</tr>
<tr>
<td>Malaria Initiative</td>
<td>Healthy Family programs</td>
</tr>
<tr>
<td>800 million treatments provided without profit since 2001, including more than 300 million pediatric treatments</td>
<td>30+ million reached in rural areas with health education and affordable treatment</td>
</tr>
</tbody>
</table>

...to reach as many people as possible
Novartis Access: Fighting the growing burden of chronic diseases

What is it?
An innovative portfolio of 15 on- and off-patent medicines to provide better care for patients suffering from cardiovascular diseases, type 2 diabetes, respiratory illnesses, and breast cancer in low- and lower-middle-income countries

Affordable treatments for most at need
The portfolio is available to governments and NGOs at an average price of USD 1 per treatment per month

75% of chronic disease deaths occur in low- and middle-income countries

75% of chronic disease deaths occur in low- and middle-income countries

WHO 2014: http://apps.who.int/iris/bitstream/10665/148114/1/9789241564854_eng.pdf?ua=1

Improving healthcare at scale
By 2020, Novartis Access aims to reach 20 million patients per year in 30 countries
Malaria Initiative: Helping to accelerate malaria elimination

What is it?
The Novartis Malaria Initiative aims to meet patient needs through four key pillars: treatment, access, capacity building, research & development

History-making
The Novartis Malaria Initiative is one of the largest access-to-medicine programs in the industry, with more than 800 million treatments delivered without profit since 2001

Gold standard
Novartis has a long heritage in antimalarial drug development
• First child-friendly ACT
• High-strength ACT for reduced pill burden
• Today, we lead two of the four most advanced malaria development programs worldwide

212 million malaria cases and 429,000 malaria deaths in 2015

Healthy Family: Health education and care for rural communities

What is it?
The Novartis Healthy Family programs use innovative business models that build local, sustainable capabilities for healthcare – including access to healthcare, education, infrastructure and distribution – for the Bottom of the Pyramid (BoP) population around the world.

Impacts at scale
Since 2010, programs in India, Kenya, Vietnam and Indonesia have reached more than 30 million people with health education.

> 4.3 million health workers are needed worldwide

WHO 2016: http://www.who.int/hrh/education/en/

Success on the ground
More than 3 million patients have been diagnosed and treated at health camps.
SMS for Life: Using mobile and digital technology to increase quality of care

What is it?
SMS for Life 2.0 uses smartphones and tablet computers to track stock levels of essential medicines. It also allows for disease monitoring and can be used to train health workers at remote facility level.

The program launched in Kaduna State, Nigeria end of 2016 and will be deployed in Zambia in 2017.

Technology for change
Originally launched in 2009, SMS for Life was designed to manage stock-outs of antimalarials. The enhanced 2.0 version now also looks at HIV treatments and vaccines and will be extended to treatments against noncommunicable diseases.

Supply chain challenges lead to medicine stock-outs in rural facilities in many lower income countries.
NGO supply: partnering with global NGOs for better access

What is it?
Sandoz has a very broad range of products which are offered to major NGO partners including UNICEF, MSF, UNDP, ICRC, The IDA Foundation. The program is committed to reaching more patients in low income and poor countries.

Our commitment to paediatric populations
We are committed to making our pediatric Amoxicillin treatments available to developing countries; to date, 500 000 treatment courses have been delivered to UNICEF. This commitment supports the UN Commission on Life-Saving Commodities for Women and Children.

6 million lives could be saved if equitable access was provided to just 13 life-saving commodities